Drugs / BCMA-UCART
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| — | NCT03752541 | Nov 2019 → Mar 2023 | plasma cell myeloma | Bioray Laboratories | Suspended | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BCMA-UCART | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03752541 ↗ |
| Action | Deplete | “these CART cells to recognize and kill BCMA-expressing MM tumor cells” NCT03752541 ↗ |
| Modality | Cell therapy | “BCMA-UCART is a kind of allogeneic CART, originating from T cells of health donors.” NCT03752541 ↗ |
| Route | Intravenous | “intravenously (IV) on day 0” NCT03752541 ↗ |